rs5210 — KCNJ11 KCNJ11 Kir6.2 Co-Variant

The Quiet Regulator — How a Non-Coding KCNJ11 Variant Shapes Insulin Secretion

Most people know that DNA variants in protein-coding regions can alter how enzymes and channels work. But rs5210 tells a more subtle story. This variant sits in the 3' untranslated region (3' UTR) of KCNJ11 — the gene encoding Kir6.2, the pore-forming subunit of the ATP-sensitive potassium (KATP) channel¹¹ ATP-sensitive potassium (KATP) channel
The KATP channel in pancreatic beta cells links glucose metabolism to insulin secretion. When glucose rises, ATP builds up, closes the channel, depolarizes the cell, and triggers insulin release. Unlike the neighboring rs5219 (E23K) missense variant, rs5210 doesn't change the Kir6.2 protein sequence at all — instead, it appears to influence how much of the protein gets made.

rs5210 is co-listed with rs5219 as a KCNJ11 co-variant, and the two SNPs are in moderate linkage disequilibrium in most populations. However, rs5210 has independent associations with both type 2 diabetes risk and sulfonylurea drug response, making it worth profiling on its own merits.

The Mechanism

The rs5210 variant lies within a conserved region of the KCNJ11 3' UTR. A meta-analysis²² A meta-analysis
Qin LJ et al. Meta-analysis of association of common variants in the KCNJ11-ABCC8 region with type 2 diabetes. Genet Mol Res, 2013 proposed that the risk allele (G) maintains a binding site for the microRNA hsa-miR-1910, while the A allele disrupts this binding site. MicroRNAs binding to the 3' UTR typically suppress gene expression by destabilizing mRNA or blocking translation³³ destabilizing mRNA or blocking translation
miRNA-3'UTR interactions are a major post-transcriptional regulatory mechanism controlling protein abundance. If the G allele retains miR-1910 binding, this could reduce KCNJ11 expression and lower Kir6.2 protein levels, leading to reduced KATP channel density in beta-cell membranes. Fewer functional channels could subtly impair the glucose-sensing mechanism.

This mechanism remains proposed rather than fully validated — the functional studies needed to confirm miR-1910 regulation of KCNJ11 in human beta cells have not yet been published. The 3' UTR location and the observed T2D association are consistent with the model, but the molecular details are still emerging.

The Evidence

The key meta-analysis⁴⁴ meta-analysis
Qin LJ et al. Genet Mol Res, 2013 analyzed 41 case-control studies encompassing 61,879 subjects across multiple populations. The rs5210 G allele showed an allelic odds ratio of 1.16 (95% CI: 1.08–1.24; P = 0.023) for type 2 diabetes — a modest but statistically robust association. For context, this effect size is comparable to the well-established rs5219 E23K variant (~OR 1.12 per allele), which has been studied far more extensively.

Beyond diabetes risk, rs5210 appears to affect drug response. In a study of T2D patients, rs5210 was associated with improved clinical efficacy of gliclazide⁵⁵ rs5210 was associated with improved clinical efficacy of gliclazide
Wang Y et al. Correlation between KCNJ11 gene polymorphisms, type 2 and post-transplant diabetes mellitus in Asian Indian population. Genes Dis, 2015, a sulfonylurea that works by binding to the SUR1 subunit and closing the KATP channel. A separate cohort study found rs5210 associated with improved fasting plasma glucose response to treatment⁶⁶ rs5210 associated with improved fasting plasma glucose response to treatment
Gloyn AL et al., 2009.

An Indian population study found rs5210 associated with T2D under a dominant model (OR 2.07, 95% CI 1.30–3.27; P = 0.001), with larger effect sizes than seen in European populations — a pattern also observed for the related rs5219 variant. The variant showed positive association with gestational diabetes and OGTT values⁷⁷ positive association with gestational diabetes and OGTT values
Gaston J et al. Indian pregnant women study, 2018 in Indian women as well.

Not all studies agree: one Iranian study found no significant association in 111 T2D cases vs 82 controls (PMID 33853507), and a 2024 GDM meta-analysis covering 3 studies found no association with gestational diabetes (PMID 38932913). The overall evidence supports a real but modest effect, with possible population heterogeneity.

Practical Actions

The clinical takeaway from rs5210 runs parallel to, but is independent of, the better-known rs5219 variant. Carriers of the G allele (the majority of people) have a mildly elevated risk of type 2 diabetes, expressed additively — two G alleles confer modestly more risk than one. The A allele is the protective minority genotype.

For sulfonylurea-treated diabetes, rs5210 G allele carriers may show better response to gliclazide specifically, and possibly to the sulfonylurea class broadly — this variant is one element of the pharmacogenomic picture your doctor can consider when calibrating doses.

Magnesium and chromium support insulin production and signaling — they are particularly relevant when beta-cell KATP channel function is subtly impaired.

Interactions

rs5210 sits approximately 1,300 bp upstream of rs5219 (E23K) in the KCNJ11 gene. The two variants are in partial linkage disequilibrium and may act in combination on KATP channel function — rs5219 at the protein level, rs5210 at the expression level. Studies examining the KCNJ11-ABCC8 region as a haplotype block consistently find both variants independently contribute to T2D and sulfonylurea pharmacogenomics.

The ABCC8 rs757110 (Ser1369Ala) variant encodes the SUR1 subunit — the other half of the KATP channel complex. ABCC8 and KCNJ11 variants together form the complete pharmacogenomic picture for sulfonylurea response. Carrying risk alleles at rs5210, rs5219, and rs757110 simultaneously is expected to compound the effect on insulin secretion, though dedicated multi-variant analysis of this specific combination is limited.